# Pfizer in Podcasts, Mar 30–Apr 5: AI and Policy Tailwinds > Weekly podcast summary for Pfizer, Mar 30–Apr 5, 2026. Body to be imported from the source email. # Pfizer ($PFE) Weekly Intelligence Brief **April 1–5, 2026 | Podcasts, News & Strategic Developments** --- ## 🎙️ Podcast Spotlight: AI-Driven Oncology & AMR Engagement Only **2 of 124 analyzed podcast episodes** this week contained substantive Pfizer discussion, reflecting limited third-party media coverage. However, the company's own corporate podcast provided detailed strategic insights, while an independent industry discussion offered critical context on antimicrobial resistance. ### **Featured Episode #1: "Science Will Win" (Pfizer Corporate Podcast)** **Guest:** Jeff Legos, Chief Oncology Officer, Pfizer **Key Themes:** - **AI Integration Across R&D Pipeline:** Legos outlined how Pfizer is deploying generative AI to synthesize external literature and proprietary data for target identification, stating: *"It's helping us identify our high-quality drug targets and thereby further increasing the odds that a promising idea makes it into early clinical development."*[1](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjnamAo84r9E9QIVecavvjzncswoe-2F89AtwancsaPfmgSsBk39CZLjHU-2FjAgHogjmNp8jthyODzJojXEl1diJ30T4FT_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApNwFG4XXzItHSiEdNBfQkMROJOUOCsT-2FsfguJ-2FqdIhzK4v3gDXsIVe4AHog1GhSbgYjJsLnSDBZDcleQVysNaeKA1dj2mdz60CpnVrCLBiyF9E4YrPkguM4laVQ0-2FPtYBQ-3D-3D) - **Partnership with Visineer:** Pfizer announced a partnership with Visineer, a healthcare AI company, to leverage AI technology in oncology clinical trials for "improving our overall response assessments, and for more precise insights on how well a drug may be working or how well a drug may not be working."[1](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjnamAo84r9E9QIVecavvjzncswoe-2F89AtwancsaPfmgSsBk39CZLjHU-2FjAgHogjmOve3YPcvBjt4wYyC9bXJA2K3uQ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApNDqE7EUG7fJIi18EL2jYXx1qPSrIlK0lwPdJsVCP7IIGeqCAnQ9-2FpQ3wXsUC9CZ-2Fyx5jPt1uqDDOQt92019KHcGTSsL1pGamN5r5T8t2STCLEoYAZgAuafjrSymEIe6xg-3D-3D) This real-time imaging analysis represents a shift from traditional endpoint-only evaluations. - **Precision Medicine Pivot:** Legos emphasized Pfizer's strategic shift: "Cancer treatments in particular have really shifted from broad, one-size-fits-all treatment to much more specialized and personalized care. This could be through targeted therapies that are focusing on molecular and genetic alterations."[1](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjnamAo84r9E9QIVecavvjzncswoe-2F89AtwancsaPfmgSsBk39CZLjHU-2FjAgHogjmOMkGTXWxssVKifqY0LB6T2j7sw_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApBntqDEodNtLQZQgthgtRkzcwhWuW4UsWkVOXgjt0xuSgF08kqeCNDiU-2BqQ8HsIA6ZqnuAvcdR0Lc2OhnfaesH48P3IazT28dzRWs6GAPDM7knJPfJoU-2Fj7yb-2Bmb0ARkVQ-3D-3D) - **Efficiency Targets:** Legos projected AI would result in "more than a doubling of our overall success rates of not only getting these new molecules into the clinic, but also ultimately translating these molecules into new and practice-changing medicines."[1](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjnamAo84r9E9QIVecavvjzncswoe-2F89AtwancsaPfmgSsBk39CZLjHU-2FjAgHogjmNU6kZNkr3Vde-2BviPmrdMZpBEUs_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApDl0UOzyrRV9w0FTSgepIY64hTGW38RvN0O-2FBQbsShT15GL3nlOzpj2cCSsuVxHKEF4fxly3uK-2BXPEZXQG0lwIYtEAbqIaev-2FfA9Uzz5eqif-2B018eBdv96kQTzJp07w2sw-3D-3D) He cited industry-wide AI-driven improvements of 30–50% timeline reductions and at least 40% cost reductions.[1](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjnamAo84r9E9QIVecavvjzncswoe-2F89AtwancsaPfmgSsBk39CZLjHU-2FjAgHogjmPP1gcXUIusrdGYDSIUBs5v5BVo_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApAoxaM5sD31US8EBYaHLRxm6qpxLLZH6HBnJI608nCeYeReS5622OznWG9w53ZqFhpfv-2Bh4NC30kSSg6z-2BI2wv0XHsD1-2Fc-2FDxemY3PE5qJ1O-2BTqrwEzJJ1TXjrLNL-2BycVA-3D-3D) **Context for Investors:** With oncology drugs costing $1–2 billion over 12–15 years and a ~90% clinical failure rate,[1](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjnamAo84r9E9QIVecavvjzncswoe-2F89AtwancsaPfmgSsBk39CZLjHU-2FjAgHogjmOUCGXZBtxsHnOzpMgS-2Bg3PYCvS_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApAUDq6hh4stIE2RRXroRx2fnYYM4X5SFDkqxcXEa2D3no-2BRqcHyWeo5EO35U9BNAC4nus3mDRCL-2FsgL9l-2FF244f-2FYbpiqAio2waiL-2FwtZKunO8L8-2F0oCnRiTaHfskSbitg-3D-3D) even modest improvements in success rates could materially impact R&D ROI. --- ### **Featured Episode #2: "The Drug Discovery World Podcast"** **Guest:** Professor Janet Hemingway, founding director, ICON Infection Innovation Consortium **Key Themes:** - **Big Pharma's AMR Absence:** Professor Hemingway noted that Big Pharma companies including Pfizer "have been absent, notably absent for quite a long time" from AMR R&D, with SMEs still responsible for 75% of antibacterial and antifungal R&D. - **Limited Re-Engagement:** While Pfizer participates in the AMR Action Fund (alongside Novartis, Takeda, and Roche) and was awarded a contract under the UK's subscription-based AMR pilot scheme with annual payments up to £20 million, Hemingway cautioned that "these machines don't move quickly and they make their decisions commercially and it won't be a quick move back into the market by those big companies." - **Insufficient Incentives:** She noted the UK incentive alone "doesn't move the dial enough for Big Pharma," suggesting Pfizer's AMR commitment remains commercially tentative pending broader global policy changes. **Investor Takeaway:** AMR represents optionality rather than a near-term revenue driver. Meaningful re-entry requires multi-country incentive alignment. --- ## 📰 Breaking News: Legal & Policy Developments ### **Court Orders €1.9B Vaccine Purchase** A Belgian court ordered Poland and Romania to accept and pay for EUR 1.9B ($2.2B) worth of Covid-19 vaccines from Pfizer, rejecting their arguments for non-compliance with a European Commission supply contract. Poland must take EUR 1.3B worth of doses and Romania EUR 600M, after both had refused delivery citing pandemic developments and other concerns.[1](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjnamAo84r9E9QIVecavvjzncswoe-2F89AtwancsaPfmgSsBk39CZLjHU-2FjAgHogjmPUWemjFCUJ5gv7C0eEA530qove_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApHEolTco121ieb5l2ygWO5HjEm7jmBsXwFk-2FnlSab-2F4gFUNOwk4eXIKlUG7Wiuhbr-2BTh-2FMhvqWCo3VLhLS12kEBVM1ytYCsB9-2B7jMv5ReQJEIGKQB1oZ0BvTOIRQkCQkQQ-3D-3D) **Financial Impact:** Represents material revenue recognition for COVID-19 franchise, which has faced declining demand. The ruling sets precedent for enforcement of EU vaccine contracts. --- ### **Tariff Exemption Secured** The Trump administration is preparing 100% tariffs on certain imported medicines, targeting companies that have not committed to increasing U.S. manufacturing. The move follows earlier threats to impose such levies on branded or patented drugs, while companies including Pfizer (PFE), AstraZeneca (AZN), and Novo Nordisk (NVO) have secured exemptions by pledging greater U.S. investment and price reductions.[1](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjnamAo84r9E9QIVecavvjzncswoe-2F89AtwancsaPfmgSsBk39CZLjHU-2FjAgHogjmNpqeLp01ZythJXmF8BlLJVTAD-_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApAE8TKLqqyjqEzRrpHppjgYc57gTwkNPDCO-2FqhWCNBjdjrEzoW37JGTQZFkBF5dBp-2BWfqLLz6eCEurUYOXYh-2BfMhCT4AtSxwgPWLhp85ktAjL2OyuK5D3VsL8l76S4Q6ng-3D-3D) **Strategic Implications:** - Pfizer avoided potentially catastrophic tariffs through manufacturing commitments - Competitors without exemptions face 100% levies, creating competitive advantage - Commitments likely include U.S. capex increases and pricing concessions - Other publicly traded companies in the space include Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).[1](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjnamAo84r9E9QIVecavvjzncswoe-2F89AtwancsaPfmgSsBk39CZLjHU-2FjAgHogjmOewAj8q5GHJW-2BlTcTxKZYzq2Mx_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApDUH0PCPObymkwQ4BWy02o4sVQZ2f-2FEydcUbCREEZsb5UNv2wNQuz7fz-2BHjhMpd3DgF7-2BnYR-2FtzLR7SelVnqXg6jmemp6aVlHEw9dxg1Nb9grE6zjW0T9c7X2FWjXViArw-3D-3D) --- ## 🔍 Strategic Analysis ### **AI Investment Thesis Validation** Pfizer's AI narrative is comprehensive but unproven. Key validation milestones to monitor: 1. **Pipeline velocity:** Are IND filings accelerating in oncology? 2. **Phase transition rates:** Do Phase 2→3 success rates improve above historical ~30%? 3. **R&D expense trajectory:** Does absolute spend decline while output increases? 4. **Visineer partnership deliverables:** Concrete trial efficiency data ### **Competitive Positioning** - **Peers making similar AI bets:** Roche (PathAI partnership), AstraZeneca (Absci collaboration), Merck (internal AI platforms) - **Differentiation unclear:** Pfizer's hybrid build-and-partner approach is pragmatic but not unique - **First-mover advantage limited:** AI infrastructure is table stakes, not differentiator ### **Policy Risk/Opportunity Matrix** --- ## 💡 Investor Action Items **Near-Term (Q2 2026):** - Monitor Q1 earnings (late April) for: - COVID vaccine revenue recognition timing from EU court ruling - R&D expense guidance and AI investment quantification - Manufacturing capex increases tied to tariff exemption **Medium-Term (2H 2026):** - Track oncology pipeline milestones for evidence of AI-driven acceleration - Compare Phase 2→3 transition rates vs. historical benchmarks - Assess competitor AI capabilities and partnerships **Long-Term (2027+):** - Evaluate whether AI investments materially improve R&D productivity metrics - Monitor global AMR policy developments for revenue optionality - Assess margin impact from U.S. manufacturing commitments and pricing concessions --- ## ⚠️ Key Limitations 1. **Source Bias:** The primary podcast source (Science Will Win) is Pfizer's own corporate communications channel. Independent verification of AI efficiency claims is unavailable. 2. **Limited Third-Party Coverage:** Only 1 of 124 podcast episodes contained independent Pfizer discussion, suggesting limited media/analyst engagement this week. 3. **No Executive Appearances:** None of the identified key figures (Bourla, Boshoff, Gottlieb, Divan, Field, Flynn, etc.) appeared on external podcasts this period. --- **Sources:** - [Science Will Win (Pfizer Podcast)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOh-2B8mD1leSQJ3h3oNtmdqeJgJ5RUHzWBv2yEXhuiHUi-2BOdaL3JuJG11vLJL41qb0npF3GxB3W9yWZFI5-2B3xo8vMP-2F9EYKN5x6R1BwFKOIje2Q-3D-3D9IW5_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApMzH6DaPJkPk1mW2q62zsW6oBwf3F8PfqAu-2FfVZeWpQsr8RkRSLS31vEtMu-2BuvQPbaLptvqSu4XR-2F5kBzfgR1gh-2BKAok37-2FISnbVj-2F3BZ66rsh8AehLEo4GfpebMchq85w-3D-3D) - [The Drug Discovery World Podcast](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjmgvJ1-2BaxsuFxPXiqle-2Bk21JHfndlhdiOPOkve-2BU6MahpOSixuEELkihfSsdgvXQ284MUpunAPKvDuoukEcHvxMYXig8Kw6wDLnSqqGY6u7A-3D-3DvJFo_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApC5Rkf9gF-2FZhq8wWHZNyFEzpzO-2FFfk7GaXuCNeEyOZ-2B4-2FzSiJLQeJkJq7eR0i8hxq8Q9HdoNg1AxE18-2F1Bvv3tRASFf0nHorto0Itpu4yd5NGkpt-2BRxWNpLBKTUXjgLvJQ-3D-3D) - [News from 2026-04-01 to 2026-04-02](various) --- *Next update: April 12, 2026* ## Additional web sources used: web[1](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIBR-2F59SoDLUeBYfD48CT2QkQnXsr13o9tpIDrsyIqxJO9-2BLKkFzh7BZshU2s9xPx137-2Fzgh7XrefKSwKq491Ycv1WsdoF2MDYkfGt0jEUa5OpD6oTSffSv04Yj-2BVyKzLCGKRO1BrHLO1tVEWRh3bFoOrLNP9cmPMbXBQvtWihDHaj3QIzCUNPVFDj0-2Bq3qDVq9XCX5poXP3Q56ESJy-2BffMke963rD29R-2BbAplBwvGDCXLELO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApI3-2FK7Nw3MXBWScUSTsPAWoTDEv5cIE7SOgynop7vtswA-2FduJngrQJjuPcTLjaukYy2W12M59Gc6IspG4OcCOy95wKnUOfBV07i57kBXEsyS4Ov4l7ECNNMxoCNtnZEKbg-3D-3D), web[2](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIENaoierf1eWIFc9AI5gmlmS1hceSjv1gACpGAfb-2BhOakbO9soiVI4xicLcZJIgJ9kMN162aycQgYXt-2FQSJ2qF-2Ba8Rx7waAvIDfQzoRxDx47knZ8PzCTWMV2ImlRQaGsRVi3zfrNCC1OIwJVF20T6EikYB5rl-2Bk9uqxrYu-2FUk-2FPTVVvXVXTjfdPti0XkeEWtrd1sWLEYs9dXkZc19ccdLb-2BktM3lSqOausHxqzKLEX4gDpfVH-2FX74G58fgwUTLOcWNQ6Mc1XltZIe84zMDgPBy4Yf2UgRSplkYRkLf5i4nqcO0PP_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApHOOLdFp6S2jHFeioWQ28rhI9QdJ-2BNKDp9hmvtR4GkbCBABUsziadjSLZGHO094-2FnYjf1pQC8bJhNdPQMuHF26jiUIr-2FYe-2BXe9NPp4lZnccVWW8LiB9LFhxVD8P3MkhR3Q-3D-3D), web[3](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIG3S83CUzC30hqzOS4ll-2Bk9R6KBjCVYMVxxWw8GDBtTAdM8L-2B9sz2pWRxVpuYIGtFss4odgKtSRNxs4yfeOjlIZEJGMfGOsiFXhwvMj4CF16NWjmN4nbjw7Jxi-2B0YF1zy5mzNpGnnugP-2FUjOSYeJ6qVfoW5XCgWBnKzEUmf-2B-2BhdpLqifZuSRvyT3-2FWxNvbQq5fHJJxVCDiCvynoF3507Vj-2FUHZ3qvJDovGYUVi2F015fTw3cMEF0SWnpB2P5jT114iDOEg-2BjGAEh-2FbyApypx77w-3Djgid_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApPj0Uy8f8ySFw1Bi0CpibPud8TR8XoyRiMAafxkhpGsUDQczONPrYXCIB36zw5LsInFpqGSzPdjhyLn85MF1GFFNhcMxKuqx8RGXnbFX85rdHYO3jPTvTn5GyqKxnKB90g-3D-3D), web[4](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIDEEsgY-2BwoBheODKYDIyPCUmq3kfJ7lJCYNKCo-2F9RVavPcvqrJc-2Fmv55b-2Feuq0cFy-2Ff3WxK56Wh7p9QHaO9HHhvyJS9ZYLvE6oMdZjEz5qe0mAfcs9GcjaZSkFVA5DxIc-2FHQtIBpvzrGsYu6D0O2qDx2o66-2FLe9cB6YQ3abUWf48VoZ1gqJqCoPNTXZFBkofm7-2BD-2F71YocFPut60WuNlSxhZxS-2FFd2npLYCPKmz74E6beD7g2pgUx-2BJxvxeRSewmwclUM5963s21S8vJsBTcxkcJ0IiFaJSlwd7IB9Bfju7gsHpF5Tr8YFjNXai5HJDUCt1lJbrbp2Tr9Pf3vKBp3BZ0GY-2FMRGBz-2BBkucbNBe1ohbjD6iIADQwiQaQoyX78Apw-3D-3D1IcS_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApDEi1-2FpEFflbCPbtgtgTCKooJJpJV04XxvKEBdGT4fln15yNHs46mJJIL-2FhxWdzpJRoPGCkTrksZ-2BZU2F4faAbShT6PR5CIjKC136XYn3-2FcRxp1EfHmLqRCmwK7g0h5BjQ-3D-3D), web[5](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIMK-2FAcM64RzH18oOueh0Fha2W7bhiBKmK00bYNM0RGX-2FLw1OsP3R0XBYxC4xVv7CmvQWCHqlIX46ooMjB4SC3O7RTXZFHQdE0swCgGOjThyvmXSgzAU5V-2Bx2PYtl38yaZWL8R5eBLOezA3L61q8JY8mIq4zoRg-2BEJYGkRtjGkO-2BjhtjvbaCPs1-2BT9sLqVP5u1EcpTYXeHqeMBnQI3u63VUGkm1Pfdj2AtpxGEQITMg10MMDY_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApFWE-2B2RVX2Y-2B8It1-2BBomk-2BSY0gnphjW9FPwtlmiF1v5KSr4BGyjDyBUUpcfi-2B1AsWTBHPrlQtx1MXyfg7uH2WUZRXcbGpSF2nir9TthyPcqXKLocoiSR8YFQDDH-2F-2BJxAQQ-3D-3D), web[6](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIBk2iTFeuNmRgeoYct0rPhNOj4X8yOZvY37iItqclc8DkbFi2p5WyLcIJmLjOkqsx9Q8hkd3bmsqfzza-2BJKbcbZcbD-2B7Amy2bJmA-2BKTdt7dKmSWnlMqjXjQt8hqLyYwBx7DUSeR7mclPDG1q-2FX8Rg3R3oO9kWCKpWuCBSaXrt987TQIrzOvKoMKu4HQGhBIY-2BCqdCQJcLi-2BL9MIT4X-2FhaYUrdrwhTYkrInNMzC-2BoLfJnXHsjjj5wOlPwMrJ6ZtqYtkqt6YEBkDuJscM-2F9Nim2No-3Dy5JY_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApAtZA6L-2F34IadnOP-2BauOREIA8fASWmu0luraU2TNNoN8S4zdXPwdXbDm4pc44PxtV2ICSHffeOcOHfJMJWhELPx9omvFkMikjhEXkQZAVbeMylbNf85Gm7BIMto2sdg9cg-3D-3D), web[7](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIHIO-2BE-2FPevZhXxCB2IwDQrb3wGsE2XZDhJNQ3gQvpb4UxX67lMSnDjFVozhT2L9tbW-2F-2FkKKCIKBij0kfoH5FG5CFXv6nm3sCcHutg3U7dv-2FiPdnQiDMfx7CmLFhSJZSM7TiXBwQIl0UCbJHH6SFYq0ogElwgzlIUvHK0VMAiE8hXjqWegPdKwciGsqImVCBFa-2F-2BioJPpXSfgvkCB6Td8EtYW0bgQJuo741ARnXcoSXPuOFU8k4VTwOi4pNEWqYPykw8n-2BA-2FvSKHabpNviYCPev3NSryhTPX6ejOvmuTVQgaGBRJ5KZvqsCwGg15nBwz9EUiFMDtHHitsf1ZgoGP3guQmla8AxajlfSeWMnWLICe-2BUJXHaUJ63BdP-2F1J8fftBzw-3D-3Dt0RJ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApFlPRO1DCUAyvoDnoFupLh0QN1OmO1hqRwlypIDLsxS4rEHc2EaLVKgMMRd4UkJT9KJ2QmvztPvhdUiAVll4Ca5FTRur7FrwhV2jGDrd-2Bzbc6jzgQbnk4hdBYYPe1qmNmQ-3D-3D), web[8](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIG3S83CUzC30hqzOS4ll-2Bk-2Fn-2BVIfW13NosDw6VeXlnuHsScUfSUETL-2Bypetmfm9U0nmJ3KYCP-2F55XMcEqIQl7EMQOdT7tmUspACOmJZdr29mjLNw5TvV4xoFlsAJVUoIrJNe-2FUnajLkyCj2isW658xKkvJR4noDLztEotsqLRoLjeWukiJO9Q3AGKlvHfJXC87BEaYUOsZq6fFcp1ruwZJ-2FgXos-2FUiUNAgVuobVdfcs2d8IjiGnubtvp-2FLU6zVVBOqnVAuDWCcI45Fdlep-2BekGI-3Drb3o_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApJK0Oc2xaOEIqThlFsWQDYyN7hiRKTlEQTFe3bkFM5ITCp1DExfy6AoT1YN8mYL48zZotNBjv5ZszmbfndrcSazadjR-2Bbgxc-2Fq1D4vjJhVyg5sCrMsd-2F5uTeSddLUcoOuQ-3D-3D), web[9](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIEpAxSbzF2SFg22DAsrtdG3Etvu1EwWerPCDDY1KJyhQkAtx9C5Yzx-2B5S4u2HnTvYP1kUogmQn-2BWd-2FP-2FbVDiXfMtTDYjYvodglGS5GSnEv-2BTvK9V7r3aLX3Z5XfC0dAuflArvwAdhyEh11USDdXII3fhlhpQbtKdyGOd5Ruw8-2FxCKtzScYuSSIMH-2BsOBa-2B8FCIiuOYohxG1arU4vBwn7uZLF7aiipLM7jTbfHafo856LzJRLSxu0MatGJdkuipjyjw-3D-3DZr4s_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApDAeto3hUWGJRw-2BMFVMPdynmAVQXTJRXbN9ROT7FbTOlYMtykcR3XfYVN1wx1-2FTuVf1PGhkR4c6oqlk-2BBwprM2TeG5DuwjuMFp6a40WdOcYaugeEs-2F38pn-2BUHp7WqiH-2FGw-3D-3D), web[10](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIPuTNcwTTdpFpP6zJhfoLoAYFQtsJsbk59bsSR89z2RRk7HMozBqYCH4cjphVVNhxteIel7e-2BXjdbIbDvywkD64Au5Iju0wR3LwClg-2B2ekQVLVhqHuGa7fLa29WV62tV9UB9Mmdtcpk6oiY3x9TQaTPEzaEWNaBCyvlIvDW7Lm4Vp51epLcE9QDxk8H4lwdvzjyUnszQlZBdjb5L2aJ7beh1Kvs4VdHMk4YFxLm7Yr80iN5SHmt-2BJ-2FXP8ycLMZac23iuUjb6LgSn8iFqwmkhLOWSW2jh1txDAOKY5vo2VryFvRvc_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApDCmfO3BfbbvISkCxIA4Rn394yOriQfa48bRW9ix6fBRMB-2FRu8Zgyc914cQR4eAzF5AKWkFKkdVuCXIWsNnUHXj0oRd5vd8n0h2OKmax-2BGqidMauOzsxXW9fIBrjli3GsA-3D-3D), web[11](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIOt46uTMb7-2Bi0RGywcdXH4s4CnBKkEhDB96M-2BkwUqM1KcdDLvsb15NBErltfQfvCfoVko772jhvFwnq3nRTGNm5VhfCee4hlvFsjVZQqBJorkTDBnUsCWXCcvBLwoIXxVWRxoGggFnDWuJGB4-2Bokixkt0fujd7DdkdpOxZzHa8ifctnmzmErvHArD9-2BwSBknlciut-2Bfo1J-2BeJVN186xNLoTbJtBPmuCWT-2Fp5zfnYb4zgI0O__7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApAAhUdLzBGKV62DT2DcYrtywKCt2Lt0fuq8AI7p1RGOU5PWF70INficvpBqQTaUMmomSKwszdbSzGNMof0FVrF7GRh-2BKxZ3bBqAH8MlJEyebFktGND9mTvvpw1EES-2BI-2Flw-3D-3D), web[12](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIJz9wYh-2B2Xb5rjy2a1wtiRmJMG8leC1CWJ-2B6IDPZz95LeDHYexFWwUgZCGlvCzRhs-2F-2Bbna8Ogfmbrk94aGS1lbaXdA87rJq7M0xXLjlXRVRV-2BmF-2BzZon63UrgCNNKTVSZuiHpBaK3MMOL-2F1r8PzllRzYrqRNtrDbL-2FKr7jbdI9s5TO0xCh-2Fw3G2wmVYPxopja9k0XorOb2os-2Bk51it83UIz15D2-2B-2F5oIF7NlZHRDHqGQCG-2BpuJsI7cVXj8YfBZUAgKAM9EJgVTrVDRH-2Br7-2F7gpbGOpQvDZ3daUBQwvgbpow3qc3SWgXYr1Hg4Sp43yeqBg-3D-3D2Otj_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApFRBmJAzDXvVBA8fWcofz-2BTFI1JtALqca6NIcTo7VfkwvmYHv1YS-2FijbEYVPq9fhSgmg-2FiBnGDZ50Gd6UMMwY9Hy-2BIEiYZBeYjAiaUJcWdF-2BFlzVOqw6leq78vefsTUslQ-3D-3D), web[13](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIIgTVs8duCjKxMwnC6Uu13H2LqZRi5wKqbnWi-2Fh1hO3lVu5VsE-2B4iHCfuTFBfPs081OSODLk6jCw-2BcpdWQ5-2B-2BqNYf2DPAhxcW5numVeZRNctYffnejtCtfGVNcm9OhrvPXsEmwkR-2BJ7cWAFJihByVTDsTNUOxpb3vJcPlBi6-2BDTxCk40TGZuqj9t0hIC5nSBkHB06WG3Ij7eQmsEOf9XGm4-3DCxoF_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApHYpepbtPpqpu75Xxk-2FhHd2-2BXtt8Y27-2BRMvEfOoBc2S8haQJXY2UFEWKaz-2BJssdBeNpNG1zQRAjJcvzOFJbRcuvK5uvUXISnv0hHTbry-2Fa5ks1DP58hbR-2BWV-2FtlIg2Yytw-3D-3D), web[14](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpINBijWYRMnr10omr8NdML1DIvfmk2OPBLQcDMX7t6F4wwcVB0RBf460eD1qX6DcGPFftr-2B-2BkJPP9mDGBIGImh87ekMwSnlpQZnWxWnGws3kiKqSLYuIn7JWMDwVoxucYvP-2Bd1CoHzI7Lrjz-2B3uPVzqGVj-2BvR0m6UsytKAQ2YxLKgfOzDd2fkJmTVV7VMkm5SicMfLsd-2F3kjhP3AuNpsBfBjo388LUdcZZD6P72cGx0ASbHYjAmjYt8NfpcNX6T0DoI-2BanqPD8ECAxNPy-2FhFmhTx7gUci-2Fk35eppHwjwTyjD6WW9wiONtHaxd-2FgtaMf79kg-3D-3DcNRR_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApATQaaoIcsrnOiu7Sk2CyzNOEURhWJqZmxM1ZImwdr-2FESe7CbJU-2F83EbQ68UH9yb3aMeP1ufL8jocE77pl2pQO6JqkJ5mSs-2Fv7kicjaAfD30eTiPksHxeUuzTPXOb-2B5i8Q-3D-3D), web[15](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIN8kZNqH5pWJgworozoPxAUzyxLuL6Swm51JTRPzJ-2FoddkKLPcymuzAci3c-2B3UcFktLwBStUrORzA19MKvpmY6JqNr6gCyoijBBXjVrbKbTdS58wk84TC9uv0-2F8cxa1zc5GaulVZf5pCD0NGIGjA9-2F8Sp-2B4Xes42Z0pb5D2NlISHBBqfuSphj5G-2Ft2C0wVjXixt9YqxISLN1pb2gdmoaDG5NHjUrz8hrIkNjwUAHbOhnurbp_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApATUanbhcB97KuhtvnU-2BJbEUSGkgaHDJnaG8ABF1mdIE-2B55jUbER-2FW67wNklXZu-2F0Aa6KAjgCY8t6-2FtLKXdlfDQ1R7peBjWGf61OAjDB2d966TpGxitk36Mw5qMqZRD13g-3D-3D), web[16](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIMG3iJ3pXnezEQcYthmOc3BeJsDaII3sGipumGwkr0NVTbqDEpnrjberzHiCTu5Xd7CTZWxXVQ0Kfl9gNSz0Wdz1CcY7jCJlTahbfOVVrdz5bnN4SuiBXfcwZEMfSLQbwoQnbpq9YZrYkQYRmFdSn1O70FGG-2F8yXGmdvEzPdDHr-2B7-2FA-2FpzLan-2BIsvZVnq4O8yhTAU-2FmwSqwXnZZeasHEeAcBFaw8tbC6gVzw7i18q0HoQ1EV_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApHa2Ni4gFQLjyQBC25H0RulUeWbzG-2F3SeMWersFkCVgqsCoboefLwBMvxMKw-2F2xp6nHkMUVLSfEDPti1ZaflwyHNUGq9dx2LYms6HmhsaAd5q-2F7hv0kX2aNGDDRKTu33Hw-3D-3D), web[17](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIDnwQeLg-2FLCjLpcfXxj1O87b-2Bq1HlKQySBibIoHYblzaiSJ8V6a4MA-2BalbE3D5lIrCe5sQnzxeiDQYMxUIkXzVzF-2B9YSTvYM8onlGDqj9Hlq65y1Wlb-2Bskm49w2iieobYu8ajekWW0A1e09MMZJVq6-2Bti5AQxNzIK8gIZdxN25rE27tiDCqOsBP-2FYYbEoT-2FtLvoDNqprP-2BT4oKiXHIVolMtEyQuG2x-2BDmm4HoPyg3QwsjX2L-2F-2FC83vf0NhTzcj-2FIH1khK3P1DmVorC-2BXkti02zw-3DjSUL_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVsgLCfwcv-2B03HIzKd35DfVlWglNCONIDZQ8ihnoMcApKZDCCZs8ChMY2vHDX-2BZkPUjlHRLuFHJlMrP6KUQXQk7bVKKe8KuevInIcrskfH45R-2BeypZ8yae9GGPsEIAh6oqSoqXP87h6E-2BdSHeVlkT3iHEMMstuyoIJSqYf5wRo8cw-3D-3D)